Inturrisi, Charles E.
Relmada Therapeutics, Inc.,
United States
2025 Rank: 43923
Overall Rank
Rank in SubField 1
Publications
Citations
Main Field:
Clinical Medicine
SubField 1:
Pharmacology & Pharmacy
SubField 2:
Neurology & Neurosurgery
Rank in SubField 1: 366 out of 157499 Researchers
Data For The Year: 2025
| Metrics | Self-Citations Excluded | All |
|---|---|---|
| Rank Based on Composite Score | 43923 | 46893 |
| Total Cites | 10487 | 11531 |
| H-index | 57 | 60 |
| Hm-index | 22 | 24 |
| Number of Single Authored Papers | 14 | 14 |
| Total Cites to Single Authored Papers | 237 | 254 |
| Number of Single+First Authored Papers | 44 | 44 |
| Total Cites to Single+First Authored Papers | 1587 | 1631 |
| Number of Single+First+Last Authored Papers | 183 | 183 |
| Total Cites to Single+First+Last Authored Papers | 5942 | 6462 |
| Composite Score | 3 | 3 |
| Number of Distinct Citing Papers | 8105 | 8542 |
| Ratio of Total Citations to Distinct Citing Papers | 1.29 | 1.35 |
| Self-Citation Percentage |
9.05%
|
|
Inturrisi, Charles E.
Relmada Therapeutics,
United States
2024 Rank: 41884
Overall Rank
Rank in SubField 1
Publications
Citations
Main Field:
Clinical Medicine
SubField 1:
Pharmacology & Pharmacy
SubField 2:
Neurology & Neurosurgery
Rank in SubField 1: 352 out of 148458 Researchers
Data For The Year: 2024
| Metrics | Self-Citations Excluded | All |
|---|---|---|
| Rank Based on Composite Score | 41884 | 45025 |
| Total Cites | 10193 | 11175 |
| H-index | 56 | 58 |
| Hm-index | 22 | 23 |
| Number of Single Authored Papers | 14 | 14 |
| Total Cites to Single Authored Papers | 231 | 247 |
| Number of Single+First Authored Papers | 42 | 42 |
| Total Cites to Single+First Authored Papers | 1541 | 1584 |
| Number of Single+First+Last Authored Papers | 181 | 181 |
| Total Cites to Single+First+Last Authored Papers | 5811 | 6325 |
| Composite Score | 3 | 3 |
| Number of Distinct Citing Papers | 7861 | 8287 |
| Ratio of Total Citations to Distinct Citing Papers | 1.30 | 1.35 |
| Self-Citation Percentage |
8.79%
|
|
Inturrisi, Charles E.
Relmada Therapeutics,
United States
2023 Rank: 39027
Overall Rank
Rank in SubField 1
Publications
Citations
Main Field:
Clinical Medicine
SubField 1:
Pharmacology & Pharmacy
SubField 2:
Neurology & Neurosurgery
Rank in SubField 1: 334 out of 140593 Researchers
Data For The Year: 2023
| Metrics | Self-Citations Excluded | All |
|---|---|---|
| Rank Based on Composite Score | 39027 | 41855 |
| Total Cites | 9890 | 10832 |
| H-index | 55 | 57 |
| Hm-index | 21 | 23 |
| Number of Single Authored Papers | 16 | 16 |
| Total Cites to Single Authored Papers | 231 | 247 |
| Number of Single+First Authored Papers | 46 | 46 |
| Total Cites to Single+First Authored Papers | 1512 | 1555 |
| Number of Single+First+Last Authored Papers | 184 | 184 |
| Total Cites to Single+First+Last Authored Papers | 5690 | 6194 |
| Composite Score | 3 | 3 |
| Number of Distinct Citing Papers | 7634 | 8053 |
| Ratio of Total Citations to Distinct Citing Papers | 1.30 | 1.35 |
| Self-Citation Percentage |
8.70%
|
|
Inturrisi, Charles E.
Weill Cornell Medicine,
United States
2021 Rank: 35532
Overall Rank
Rank in SubField 1
Publications
Citations
Main Field:
Clinical Medicine
SubField 1:
Pharmacology & Pharmacy
SubField 2:
Neurology & Neurosurgery
Rank in SubField 1: 315 out of 131063 Researchers
Data For The Year: 2021
| Metrics | Self-Citations Excluded | All |
|---|---|---|
| Rank Based on Composite Score | 35532 | 37372 |
| Total Cites | 9261 | 10131 |
| H-index | 54 | 56 |
| Hm-index | 21 | 23 |
| Number of Single Authored Papers | 14 | 14 |
| Total Cites to Single Authored Papers | 203 | 218 |
| Number of Single+First Authored Papers | 42 | 42 |
| Total Cites to Single+First Authored Papers | 1401 | 1443 |
| Number of Single+First+Last Authored Papers | 180 | 180 |
| Total Cites to Single+First+Last Authored Papers | 5352 | 5834 |
| Composite Score | 3 | 3 |
| Number of Distinct Citing Papers | 7117 | 7502 |
| Ratio of Total Citations to Distinct Citing Papers | 1.30 | 1.35 |
| Self-Citation Percentage |
8.59%
|
|
Related Profiles
Featured Profiles
Partner with TOPSCINET
Reach science enthusiasts and researchers across the site. Write to business@topscinet.com and our marketing team will send a proposal built around your banner ad goals.